Italy's Diasorin confirms 2026 guidance, sees 6-8% yearly sales growth until 2030
20/05/2026 10:34
May 20 (Reuters) - Italy's Diasorin DIAS.MI confirmed its 2026 guidance on Wednesday and announced a new 2026-2030 business plan ahead of a presentation to investors. The medical diagnostics firm said it expected average revenue growth of 6% to 8% per year at constant exchange rates between 2026 and 2030. That is slightly above the 5% to 6% growth guidance for 2026. (Reporting by Anna Uras, editing by Milla Nissi-Prussak) ((Anna.Uras@thomsonreuters.com;))
Recent news on Diasorin
See all newsEquita upgrades Diasorin, sees 'solid' Q3
Brief: Diasorin Obtained FDA Approval For Fully Automated Laboratory Serology Tests For Human Parvovirus B19 Igm And Human Parvovirus B19 Igg On The Liaison Xl
Europe Research Roundup: Allianz, Mercedes-Benz, Tesco
European life sciences stocks rise on strong sector momentum
Italy - Factors to watch on September 21